// App-Quantinova.ai

3490 : The effect of novel CYP17 inhibitor galeterone on gonadal and tumor progestogen and androgen levels in SCID mice bearing LNCaP prostate cancer xenografts

Researchers

Presenter

  • Amanda J. Schech

Principal Investigators

  • Gauri J. Sabnis

  • Stephen Yu

  • Vincent C.O. Njar

  • Douglas B. Jacoby

  • Peter Nelson

  • Ruth Dumpit

  • Angela M.H. Brodie

Medical Centers

  • University of Maryland School of Medicine, Baltimore, MD

  • Tokai Pharmaceuticals, Boston, MA

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Primary aldosteronism

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • Cortisol

  • Cytochrome P450 Family 17 subfamily A member 1

Drug/Treatment

  • prasterone

  • Hydroxyprogesterone caproate

  • pregnenolone

  • progestogen

  • Galeterone

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved